During trastuzumab treatment, LVEF and GLS were additionally reduced, and the mean LVEF was significantly lower in patients with HER2-positive breast cancer (61.3 vs. 66.0%, p = 0.04) (Figure 4C,D). Here, ERBB2 is linked to breast cancer.